| Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption JJ Wilkins, RM Savic, MO Karlsson, G Langdon, H McIlleron, G Pillai, ... Antimicrobial agents and chemotherapy 52 (6), 2138-2148, 2008 | 195 | 2008 |
| Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery CH Wilder-Smith, L Hill, J Wilkins, L Denny The Journal of the American Society of Anesthesiologists 91 (3), 639-639, 1999 | 160 | 1999 |
| Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson British journal of clinical pharmacology 72 (1), 51-62, 2011 | 136 | 2011 |
| Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of … M Joerger, ADR Huitema, DJ Richel, C Dittrich, N Pavlidis, E Briasoulis, ... Clinical Cancer Research 13 (21), 6410-6418, 2007 | 133 | 2007 |
| Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson European journal of clinical pharmacology 62, 727-735, 2006 | 105 | 2006 |
| Population pharmacokinetics of ethambutol in South African tuberculosis patients S Jönsson, A Davidse, J Wilkins, JS Van der Walt, USH Simonsson, ... Antimicrobial agents and chemotherapy 55 (9), 4230-4237, 2011 | 83 | 2011 |
| Time‐varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma JJ Wilkins, B Brockhaus, H Dai, Y Vugmeyster, JT White, S Brar, CL Bello, ... CPT: Pharmacometrics & Systems Pharmacology 8 (6), 415-427, 2019 | 59 | 2019 |
| Nonlinear mixed‐effects model development and simulation using nlmixr and related R open‐source packages M Fidler, JJ Wilkins, R Hooijmaijers, TM Post, R Schoemaker, MN Trame, ... CPT: pharmacometrics & systems pharmacology 8 (9), 621-633, 2019 | 52 | 2019 |
| NONMEMory: a run management tool for NONMEM JJ Wilkins Computer methods and programs in biomedicine 78 (3), 259-267, 2005 | 50 | 2005 |
| Changing body weight–based dosing to a flat dose for avelumab in metastatic merkel cell and advanced urothelial carcinoma AM Novakovic, JJ Wilkins, H Dai, JR Wade, B Neuteboom, S Brar, ... Clinical Pharmacology & Therapeutics 107 (3), 588-596, 2020 | 39 | 2020 |
| Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment BJ Brennan, K Wang, S Blotner, MO Magnusson, JJ Wilkins, P Martin, ... Antimicrobial agents and chemotherapy 57 (12), 6097-6105, 2013 | 37 | 2013 |
| Open innovation: Towards sharing of data, models and workflows DJ Conrado, MO Karlsson, K Romero, C Sarr, JJ Wilkins European Journal of Pharmaceutical Sciences 109, S65-S71, 2017 | 36 | 2017 |
| Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis G Langdon, JJ Wilkins, PJ Smith, H McIlleron The International Journal of Tuberculosis and Lung Disease 8 (7), 862-867, 2004 | 35 | 2004 |
| Single-dose pharmacokinetics and tolerability of oral delta-9-tetrahydrocannabinol in patients with amyotrophic lateral sclerosis M Joerger, J Wilkins, S Fagagnini, R Baldinger, R Brenneisen, ... Drug metabolism letters 6 (2), 102-108, 2012 | 29 | 2012 |
| Patterns and power for the visual predictive check J Wilkins, M Karlsson, EN Jonsson 15th meeting of the Population Approach Group in Europe, Brugges, Belgium …, 2006 | 25 | 2006 |
| Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients G Langdon, J Wilkins, L McFadyen, H McIlleron, P Smith, USH Simonsson Antimicrobial agents and chemotherapy 49 (11), 4429-4436, 2005 | 21 | 2005 |
| informativeness of empirical Bayes estimate-based diagnostics RM Savic, JJ Wilkins, MO Karlsson AAPS J 8, T3360, 2006 | 20 | 2006 |
| Selection of the recommended phase 2 dose for bintrafusp alfa, a bifunctional fusion protein targeting TGF‐β and PD‐L1 Y Vugmeyster, J Wilkins, A Koenig, S El Bawab, I Dussault, LS Ojalvo, ... Clinical Pharmacology & Therapeutics 108 (3), 566-574, 2020 | 18 | 2020 |
| Population pharmacokinetic analysis of bintrafusp alfa in different cancer types JJ Wilkins, Y Vugmeyster, I Dussault, P Girard, A Khandelwal Advances in Therapy 36, 2414-2433, 2019 | 16 | 2019 |
| Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis P Chen, P Olsson Gisleskog, JJ Perez‐Ruixo, J Xiao, J Wilkins, ... CPT: pharmacometrics & systems pharmacology 5 (9), 484-494, 2016 | 15 | 2016 |
